Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
hema.to GmbH logo — AI cytometry to advance precision immune medicine

hema.to GmbH

AI cytometry to advance precision immune medicine

Founded 2021 Germany Germany 16 employees Seed Total: $7.20M AI, Health Care

General Information

Company Name hema.to GmbH
Founded Year 2021
Location Germany Germany
Employees 16
Industries AI, Health Care
Funding Stage Seed
Business Model B2B, SaaS
Revenue Model Subscription, Usage Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with hema.to GmbH. To contact hema.to GmbH, visit hema.to.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does hema.to GmbH compare?

A PDF of hema.to GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting hema.to GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About hema.to GmbH

hema.to GmbH, founded in 2021, is a deeptech AI company based in Germany with a mission exemplified by their slogan, "AI cytometry to advance precision immune medicine." The company focuses on innovating within the healthcare sector by leveraging artificial intelligence to enhance cytometry, ultimately aiming to tailor treatment plans to fit the unique immune profiles of individual patients.

Their dedication to transforming immune medicine has attracted financial backing, culminating in a recent €3.60M seed investment on 01 February 2025. This funding round was supported by prominent European investors, including High-Tech Gründerfonds, Bayern Kapital, Elaia Partners, Heal Capital, and LUMO labs. The strategic investment underscores investor confidence in hema.to's potential to make a significant impact on personalized healthcare solutions using cutting-edge AI technologies.

Business keywords: Deeptech, AI-powered Cytometry, Precision Immune Medicine, Automated Blood Cancer Detection, Flow Cytometry, Healthcare Innovation, Immune System Analysis, Personalized Medicine, Digital Health, Medical Diagnostics, Cancer Treatment Optimization

Services & Products

AI-driven cytometry solutions
Workflow automation
Diagnostic support for B-NHL
Real-time collaborative tools
Cloud-based workflow platforms

Target Customers

Hematology labs Clinical diagnostics labs Medical professionals in hematopathology Research laboratories Laboratories focusing on B-NHL

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed €3.60M 5
High-Tech Gründerfonds Bayern Kapital Elaia Partners
High-Tech Gründerfonds, Bayern Kapital +3
01 Feb 2025
Seed €3.60M 3
High-Tech Gründerfonds Elaia Partners Heal Capital
High-Tech Gründerfonds, Elaia Partners +1
01 Jun 2023

hema.to GmbH Alternatives & Competitors

View All Alternatives
hema.to GmbH vs
CliniNote - unlocking clinical data
CliniNote - unlocking clinical data Poland

Unlocking power of clinical data.

Seed
15 employees
AI, Analytics
hema.to GmbH vs
Novigenix SA
Novigenix SA Switzerland

Leader in Immuno-Transcriptomic Precision Medicine solutions

Series B
26 employees
AI, Analytics
hema.to GmbH vs
Tempus AI
Tempus AI United States

Tempus AI, Inc. (NASDAQ: TEM) is a technology company leading the adoption of AI to advance precisio...

IPO
3178 employees
AI, Biotechnology
View all alternatives

FAQ About hema.to GmbH

AI cytometry to advance precision immune medicine
hema.to GmbH was founded in 2021.
hema.to GmbH is headquartered in Germany.
hema.to GmbH operates in AI and Health Care. Its work centres on Deeptech, AI-powered Cytometry, Precision Immune Medicine and Automated Blood Cancer Detection. Its customers include Hematology labs, Clinical diagnostics labs and Medical professionals in hematopathology.
hema.to GmbH has a B2B and SaaS business model. Its revenue comes from Subscription, Usage Based and Service Fee.
hema.to GmbH has approximately 16 employees.
hema.to GmbH has completed 2 funding rounds, raising a total of $7.20M. The latest funding stage is Seed.
hema.to GmbH offers: AI-driven cytometry solutions, Workflow automation, Diagnostic support for B-NHL, Real-time collaborative tools, Cloud-based workflow platforms.
Top alternatives and competitors to hema.to GmbH include CliniNote - unlocking clinical data, Novigenix SA, Tempus AI, Sight Diagnostics, MVision AI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
hema.to GmbH and CliniNote - unlocking clinical data are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for hema.to GmbH, https://bouncewatch.com/company/hemato, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout